In today’s broadcast from Dirket Studios, NanoEcho’s CEO, Linda Persson, participated. During the interview, Linda discusses the recently completed equity issue, this week’s listing on Nasdaq First North Growth Market, and NanoEcho’s future focus areas.
Watch the full interview in Swedish here 👇
NanoEcho’s innovative method, with its high precision, aims to facilitate the differentiation between diseased and healthy tissue and at the same time determine a more precise localization of cancerous tissue. The goal is to provide a more reliable diagnosis of, for example cancer diseases, that has the potential to contribute to cost-effectiveness in the health care.
Not For Sale – For Clinical Investigation Use Only – EU Trial No.: 2024-515335-29-00